$1.33

0.13 (10.83%)

10/13/2008 3:59 PM

SuperGen, Inc. (SUPG)

CAPS Rating:

A pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

SUPG doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

137 Outperforms

6 Underperforms

All-Stars

36 Outperforms

2 Underperforms

Wall Street

3 Outperforms

1 Underperforms

Members bullish on SUPG are also bullish on:

Members bearish on SUPG are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), Micro Cap (4824)
Suggest a tag

SuperGen, Inc. At A Glance

Current Price:	$1.33
Last Trade Time:	10/13/2008 3:59 PM
Open:	$1.20
Previous Close:	$1.20
Daily Range:	$1.18 - $1.35
52-Week Range:	$1.11 - $4.67
Volume:	220,915
Market Cap:	$69.07M
P/E Ratio:	7.30
Compare Our Special Broker Offers!

Stock Trends

SUPG VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for SUPG

Celgene shares rise as Cowen upgrades stock
10/8/2008 9:08:00 PM - AP
SuperGen drug candidate gets special designation
8/7/2008 9:24:00 AM - AP
Celgene shares rise as rival's drug fails study
7/1/2008 6:43:00 PM - AP
S&P 500 Leaders & Laggards: S&P 500
7/1/2008 5:58:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 SuperGen, Inc. (SUPG)

Avatar zzlangerhans (99.10) Submitted: 2/11/08 12:29 PM

It seems like a good time to drop a green thumb on Supergen because the share price has been beaten down consistently for the past year, along with 90% of the small cap biotechs. But Supergen actually gets revenue from a real product, Dacogen for myelodysplastic syndrome. Revenues in the last quarte...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 21 : 1 2 3 4 5 Next »

Recs 0 (SUPG) stockmarkid (99.39) Submitted: 7/22/08 1:03 PM : Start Price: $1.82 SUPG Score: -1.64 The disappointing EORTC trial of Dacogen will likely stop EU marketing application by JNJ and Dacogen loosing market share to Vidaza. I believe the ultimate success of Supergen would have been at least equal in success with Vidaza trial to maintain its market share in the US and pursuing JNJ application in the EU. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SUPG) biovestor (20.92) Submitted: 6/28/08 6:19 AM : Start Price: $2.20 SUPG Score: -9.86 A cancer biotech stock trading for near cash with zero debt with pending EORTC survival data due shortly for Dacogen likley to support EU marketing application by JNJ. Dacogen is already apporved in USA and SUPG has a robust, early-stage cancer piepline and discovery platform in place. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SUPG) NWTOGME (< 20) Submitted: 5/30/08 1:58 AM : Start Price: $2.48 SUPG Score: -10.33 At bottom price NO dept royalty income,pe low why not. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (SUPG) azballgofar (< 20) Submitted: 2/25/08 1:38 PM : Start Price: $2.46 SUPG Score: -12.39 Has been looking kind of doggey but there are events to be disclosed. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (SUPG) zzlangerhans (99.10) Submitted: 2/11/08 12:29 PM : Start Price: $2.94 SUPG Score: -22.31 It seems like a good time to drop a green thumb on Supergen because the share price has been beaten down consistently for the past year, along with 90% of the small cap biotechs. But Supergen actually gets revenue from a real product, Dacogen for myelodysplastic syndrome. Revenues in the last quarter were 6 million. Getting Dacogen approved and on the market seems to have done nothing but hurt the stock. Some pressure exists from Vidaza, a competing drug from Pharmion which was demonstrated to confer a survival advantage to MDS patients last year. But a similar trial for Dacogen, ADOPT, is scheduled to be completed early this year. Positive data could send Supergen flying back up. Either way, an enterprise value of 88M seems low given annual Dacogen revenues of 25 million and an admittedly tentative pipeline of tyrosine kinase inhibitors. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 21 : 1 2 3 4 5 Next »

Wall Street

Results 1 - 4 of 4

picks per page. CHANGE

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackRodmanRen	68.33	07/02/08		NS	$2.15	-38.14%	-30.24%	-7.90
	TrackSusquehanna	68.85	07/02/08		NS	$2.15	-38.14%	-30.24%	-7.90
	TrackAmTechJSA	85.86	09/05/07		NS	$4.19	-68.26%	-39.24%	-29.02
	TrackJimCramer	77.11	08/03/07		3W	$5.04	-73.61%	-37.47%	+36.14

Results 1 - 4 of 4

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.